HSBC Holdings plc vs Liquidia Corporation Common Stock — how do they compare? HSBC Holdings plc trades at $94.58 (market cap $322.45B), while Liquidia Corporation Common Stock trades at $33.81 (market cap $3.04B). The key difference: HSBC Holdings plc is far larger — about 106.1× Liquidia Corporation Common Stock's market cap, and HSBC Holdings plc pays a 3.99% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Liquidia Corporation Common Stock for 0 Days on average.
| HSBC | LQDA | |
|---|---|---|
Market Cap | $322.45B | $3.04B |
Volume | 2,058,215 | 21,111,778 |
Sector | Financials | Health |
52-Week High | $107.86 | $91.03 |
52-Week Low | $65.67 | $22.02 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.52B | $2.94B |
Dividend Yield | 3.99% | — |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with mixed technical signals showing bearish momentum but neutral oscillators. The bank demonstrates strong profitability with a 34.54% net income margin and reasonable valuation at 13.42 P/E. Recent strategic moves include expanding US wealth services and re-entering India's equity broking market, while analyst sentiment remains divided with 38% buy ratings.
HSBC presents a balanced opportunity with solid fundamentals and global expansion initiatives, though technical weakness and CFO transition risks warrant caution. The stock's current valuation appears reasonable relative to earnings power, but investors should monitor execution of growth strategies amid competitive banking landscape and potential macroeconomic headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →